Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s Dement. 2020;6:e12050.
Lin PJ, Cohen JT, Neumann PJ. Preparing the health-care system to pay for new Alzheimer’s drugs. Alzheimer’s Dement. 2020;16:1568–70.
Rainville C, Skufca L, Mehegan L. Family caregiving and out-of-pocket costs: 2016 report [Internet]. Washington, DC: AARP; 2016. https://doi.org/10.26419/res.00138.001.
Kasper JD, Freedman VA, Spillman BC, Wolff JL. The disproportionate impact of dementia on family and unpaid caregiving to older adults. Health Aff. 2015;34:1642–9.
Costa N, Derumeaux H, Rapp T, Garnault V, Ferlicoq L, Gillette S, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev. 2012;2:1–12.
Mauskopf J, Mucha L. A review of the methods used to estimate the cost of Alzheimer’s disease in the United States. Am J Alzheimers Dis Other Dement. 2011;26:298–309.
Jönsson L, Lin PJ, Khachaturian AS. Special topic section on health economics and public policy of Alzheimer’s disease. Alzheimer’s Dement. 2017;13:201–4.
El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the Iceberg: assessing the global socioeconomic costs of Alzheimer’s disease and related dementias and strategic implications for stakeholders. J Alzheimer’s Dis. 2019;70:321–39.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. J Am Med Assoc. 2016;316:1093–103.
Trenaman L, Pearson SD, Hoch JS. How are incremental cost-effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States? Value Health. 2020;23:576–84.
Neumann PJ, Silver MC, Cohen JT. Should a drug’s value depend on the disease or population it treats? Insights from ICER’s value assessments [Internet]. Health Aff Blog. 2018 [cited 2021 Apr 3]. Available from: https://www.healthaffairs.org/do/10.1377/hblog20181105.38350/full/.
Mcqueen RB, Slejko JF. Toward modified impact inventory tables to facilitate patient-centered value assessment. Pharmacoeconomics. 2021;39:379–82.
dosReis S, Butler B, Caicedo J, Kennedy A, Hong YD, Zhang C, et al. Stakeholder-engaged derivation of patient-informed value elements. Patient. 2020. https://doi.org/10.1007/s40271-020-00433-8.
Slejko JF, Mattingly TJ II, Mullins CD, Perfetto EM, DosReis S. Future of patients in healthcare evaluation: the patient-informed reference case. Value Health. 2019;22:545–8.
Andersen K, Lolk A, Martinussen T, Kragh-Sørensen P. Very mild to severe dementia and mortality: a 14-year follow-up—the Odense study. Dement Geriatr Cogn Disord. 2010;29:61–7.
Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501–9.
Lin PJ, D’Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer’s disease interventions. Pharmacoeconomics. 2019;37:597–608. https://doi.org/10.1007/s40273-019-00788-3.
Neumann PJ, Kuntz KM, Leon J, Araki SS, Richard C, Hsu M, Weinstein MC. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37:27–32.
Beard RL, Fetterman DJ, Wu B, Bryant L. The two voices of alzheimer’s: attitudes toward brain health by diagnosed individuals and support persons. Gerontologist. 2009;49:S40–9.
Majoni M, Oremus M. Does being a retired or employed caregiver affect the association between behaviours in Alzheimer’s disease and caregivers’ health-related quality-of-life? BMC Res Notes. 2017;10:1–6.
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res. 2017;17:189–202.
van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311–9.
Biogen. Aducanumab for the treatment of Alzheimer’s disease. In: Food Drug Adm. Peripher. Cent. Nerv. Syst. Drugs Advis. Comm. 2020.
Basu A. Estimating costs and valuations of non-health benefits in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness heal. med. 2nd ed. New York: Oxford University Press; 2017. p. 201–35.
Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer’s disease care. Health Aff. 1993;12:164–76.
Gandy S. 6 ways the FDA’s approval of Aduhelm does more harm than good [Internet]. Stat. 2021 [cited 2021 Jul 25]. Available from: https://www.statnews.com/2021/06/15/6-ways-fda-approval-aduhelm-does-more-harm-than-good/?utm_source=STAT+Newsletters&utm_campaign=968f7ea0c1-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-968f7ea0c1-153352634.
Nicholas LH, Langa KM, Bynum JPW, Hsu JW. Financial presentation of Alzheimer disease and related dementias. JAMA Intern Med. 2021;181:220–7.
Kokorelias KM, Gignac MAM, Naglie G, Rittenberg N, MacKenzie J, D’Souza S, et al. A grounded theory study to identify caregiving phases and support needs across the Alzheimer’s disease trajectory. Disabil Rehabil. 2020. https://doi.org/10.1080/09638288.2020.1788655.
Fitzpatrick T, Perrier L, Shakik S, Cairncross Z, Tricco AC, Lix L, et al. Assessment of long-term follow-up of randomized trial participants by linkage to routinely collected data: a scoping review and analysis. JAMA Netw Open. 2018;1:e186019.
Rajamaki B, Hartikainen S, Tolppanen AM. The effect of comorbidities on survival in persons with Alzheimer’s disease: a matched cohort study. BMC Geriatr. 2021;21:1–9.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.
Wolff JL, Mulcahy J, Roth DL, Cenzer IS, Kasper JD, Huang J, et al. Long-term nursing home entry: a prognostic model for older adults with a family or unpaid caregiver. J Am Geriatr Soc. 2018;66:1887–94.
Makin S. The amyloid hypothesis on trial. Nature. 2018;559:S4-7.
Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, Gold AL, Manly JJ, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.
Bognar K, Romley JA, Bae JP, Murray J, Chou JW, Lakdawalla DN. The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. J Health Econ. 2017;51:1–12.
Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data Task Force report. Value Health. 2007;10:326–35.
Sullivan P, Goldmann D. The promise of comparative effectiveness research. JAMA. 2011;305:400–1.
Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Mak. 2012;32:678–89.
Green C, Handels R, Gustavsson A, Wimo A, Winblad B, Sköldunger A, et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: an open-source modeling framework. Alzheimer’s Dement. 2019;15:1309–21.
IPECAD: International Pharmaco-Economic Collaboration on Alzheimer’s Disease [Internet]. 2021. Available from: http://www.ipecad.org.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices Task Force-7. Med Decis Mak. 2012;32:733–43.
Patient-Centred Outcomes Research Institute. Principles for the consideration of the full range of outcomes data in PCORI-funded research [Internet]. 2021. Available from: https://www.pcori.org/research-results/about-our-research/principlesconsideration-full-range-outcomes-data-pcori-funded-research
Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context—a health economics approach: an ISPOR special Task Force report . Value Health. 2018;21:124–30.
Mattingly TJ II, Slejko JF, Perfetto EM, Kottilil S, Mullins CD. What matters most for treatment decisions in hepatitis C: effectiveness, costs, and altruism. Patient. 2019;12:631–8.
Mattingly II TJ, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis. Pharmacoeconomics. 2020;38:233–42.
Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics. 2009;27:705–12.
Musiek ES, Morris JC. Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease. J Am Med Assoc. 2021;78:141–2.
Liu JL, Hlavka JP, Hillestad R, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer’s treatment. RAND; 2017.
Oremus M. Systematic review of economic evaluations of Alzheimer’s disease medications. Expert Rev Pharmacoecon Outcomes Res. 2008;8:273–89.
DaDalt O, Coughlin JF. Managing financial well-being in the shadow of Alzheimer’s disease. Public Policy Aging Rep. 2016;26:36–8.